CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 28,754	$ 27,116	$ 27,281
Costs and expenses:
Cost of goods sold	6,251	6,498	5,657
Research and development expenses	5,907	5,718	4,977
Acquired in-process research and development expenses	4,663	1,155	944
In-process research and development impairments	4,180	50	2,700
Selling, general and administrative expenses	6,091	6,090	5,673
Total costs and expenses	27,092	19,511	19,951
Operating income	1,662	7,605	7,330
Interest expense	977	944	935
Other income (expense)	(6)	(198)	581
Income before income taxes	690	6,859	5,814
Income tax expense	211	1,247	1,248
Net income	480	5,613	4,566
Net loss attributable to noncontrolling interest	0	(52)	(26)
Net income attributable to Gilead	$ 480	$ 5,665	$ 4,592
Basic earnings per share attributable to Gilead (in dollars per share)	$ 0.38	$ 4.54	$ 3.66
Shares used in basic earnings per share attributable to Gilead calculation (in shares)	1,247	1,248	1,255
Diluted earnings per share attributable to Gilead (in dollars per share)	$ 0.38	$ 4.50	$ 3.64
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)	1,255	1,258	1,262
Product sales
Revenues:
Total revenues	$ 28,610	$ 26,934	$ 26,982
Royalty, contract and other revenues
Revenues:
Total revenues	$ 144	$ 182	$ 299